A compass that points to lupus: Genetic studies on type I interferon pathway

Genes and Immunity

Volumn 8, Issue 6, 2007, Pages 445-455

  Kyogoku, C ^a,b   Tsuchiya, N ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 5; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

CAUCASIAN; EXON; EXPERIMENTAL MODEL; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MAPPING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; IMMUNOASSAY; IMMUNOPATHOGENESIS; INTRON; MUTATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGEN-ANTIBODY COMPLEX; DENDRITIC CELLS; GENE EXPRESSION PROFILING; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TOLL-LIKE RECEPTORS;

EID: 34548433979     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364409     Document Type: Review

References (104)

1. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5-8.
2. Ytterberg SR, Schnitzer TJ: Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982; 25: 401-406.
3. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. Systemic lupus erythematosus: Presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982; 216: 429-431.
4. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000; 9: 664-671.
5. Kalkner KM, Ronnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998, 91: 393-399.
6. Ronnblom LE, Alm GV, Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 1991; 30: 537-540.
7. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003; 36: 511-518.
8. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004; 75: 504-507.
9. Alarcon-Riquelme ME. A RUNX trio with a taste for autoimmunity. Nat Genet 2003; 35: 299-300.
10. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615.
11. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
12. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3958-3967.
13. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3: E491.
14. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-267.
15. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307-336.
16. Stewart TA. Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev 2003; 14: 139-154.
17. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science 2002; 296: 1653-1655.
18. Perniok A, Wedekind F, Herrmann M, Specker C, Schneider M. High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus 1998; 7: 113-118.
19. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1241-1250.
20. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 1317-1330.
21. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999; 115: 196-202.
22. Vallin H, Perers A, Alm GV, Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol 1999; 163: 6306-6313.
23. Bave U, Alm GV, Ronnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. J Immunol 2000; 165 3519-3526.
24. Bave U, Vallin H, Alm GV, Ronnblom L. Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 2001; 17 71-80.
25. Magnusson M, Magnusson S, Vallin H, Ronnblom L, Alm GV. Importance of CpG dinucleotides in activation of natural IFN-alpha-producing cells by a lupus-related oligodeoxynucleotide. Scand J Immunol 2001; 54 543-550.
26. Ronnblom L, Alm GV. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001; 194: F59-F63.
27. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 2003; 171 3296-3302.
28. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19: 225-234.
29. Medzhitov R, Preston-Hurlburt P, Janeway Jr CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-397.
30. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006; 13: 816-825.
31. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7: 131-137.
32. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-995.
33. Liu YJ. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005; 23: 275-306.
34. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5: 1219-1226.
35. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303: 1526-1529.
36. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408 740-745.
37. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-607.
38. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168 4531-4537.
39. Reeves JP, Taurog JD, Steinberg AD. Polyclonal B-cell activation of autoantibodies (CBA/N x NZB)F1 mice by polyinosinic polycytidylic acid. Clin Immunol Immunopathol 1981; 19: 170-180.
40. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777-788.
41. Braun D, Geraldes P, Demengeot J. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003; 20: 15-25.
42. Kono DH, Baccala R, Theofilopoulos AN. Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor. Autoimmunity 2003; 36: 503-510.
43. Nicoletti F, Di Marco R, Zaccone P, Xiang M, Magro G, Grasso S et al. Dichotomic eftects or IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr/lpr mice. Eur J Immunol 2000; 30: 438-447.
44. Richards HB, Satoh M, Jennette JC, Croker BP, Yoshida H, Reeves WH. Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int 2001; 60: 2173-2180.
45. Lawson BR, Prud'homme GJ, Chang Y, Gardner HA, Kuan J, Kono DH et al. Treatment of murine lupus with CDNA encoding IFN-gammaR/Fc. J Clin Invest 2000; 106: 207-215.
46. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-1503.
47. Rozzo SJ, Allard JD, Choubey D, Vyse TJ, Izui S, Peltz G et al. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 2001; 15: 435-443.
48. Min W, Ghosh S, Lengyel P. The interferon-inducible p202 protein as a modulator of transcription: Inhibition of NF-kappa B, c-Fos, and c-Jun activities. Mol Cell Biol 1996; 16: 359-368.
49. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003; 4: 177-186.
50. Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003; 5: 279-287.
51. Ye S, Pang H, Gu YY, Hua J, Chen XG, Bao CD et al. Protein interaction for an interferon-inducible systemic lupus associated gene, IFIT1. Rheumatology 2003; 42: 1155-1163.
52. Baechler EC, Batliwalla FM, Reed AM, Peterson EJ, Gaffney PM, Moser KL et al. Gene expression profiling in human autoimmunity. Immunol Rev 2006; 210: 120-137.
53. Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2004; 16: 801-807.
54. Shao W, Zhou Z, Laroche I, Lu H, Zong Q, Patel DD et al. Optimization of rolling-circle amplified protein microarrays for multiplexed protein profiling. J Biomed Biotechnol 2003; 2003 299-307.
55. Perlee L, Christiansen J, Dondero R, Grimwade B, Lejnine S, Mullenix M et al. Development and standardization of multiplexed antibody microarrays for use in quantitative proteomics. Proteome Sci 2004; 2: 9.
56. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
57. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
58. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002; 32: 666-669.
59. Kyogoku C, Dijstelbloem HM, Tsuchiya N, Hatta Y, Kato H, Yamaguchi A et al. Fcg receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: Contribution of FCGR2B to genetic susceptibility. Arthritis Rheum 2002; 46: 1242-1254.
60. Tsuchiya N, Kyogoku C. Role of Fcg receptor IIb polymorphism in the genetic background of systemic lupus erythematosus: Insights from Asia. Autoimmunity 2005; 38: 347-352.
61. Kono H, Kyogoku C, Suzuki T, Tsuchiya N, Honda H, Yamamoto K et al. FcgRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet 2005; 14: 2881-2892.
62. Tsuchiya N, Honda Z, Tokunaga K. Role of B cell inhibitory receptor polymorphisms in systemic lupus erythematosus: A negative times a negative makes a positive. J Hum Genet 2006; 51: 741-750.
63. Wu H, Boackle SA, Hanvivadhanakul P, Ulgiati D, Grossman JM, Lee Y et al. Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus. Proc Natl Acad Sci USA 2007; 104: 3961-3966.
64. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005; 76: 528-537.
65. Decker T, Stockinger S, Karaghiosoff M, Muller M, Kovarik P. IFNs and STATs in innate immunity to microorganisms. J Clin Invest 2002; 109: 1271-1277.
66. Honda K, Taniguchi T. IRFs: Master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006; 6: 644-658.
67. Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001; 276: 23382-23390.
68. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001; 19: 623-655.
69. Izaguirre A, Barnes BJ, Amrute S, Yeow WS, Megjugorac N, Dai J et al. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J Leukocyte Biol 2003; 74: 1125-1138.
70. Mancl ME, Hu G, Sangster-Guity N, Olshalsky SL, Hoops K, Fitzgerald-Bocarsly P et al. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. J Biol Chem 2005; 280 21078-21090.
71. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115: 407-417.
72. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005; 202: 1131-1139.
73. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004; 199: 1631-1640.
74. Honda K, Yanai H, Takaoka A, Taniguchi T. Regulation of the type I IFN induction: A current view. Int Immunol 2005; 17: 1367-1378.
75. Negishi H, Ohba Y, Yanai H, Takaoka A, Honma K, Yui K et al. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci USA 2005; 102: 15989-15994.
76. Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 2002; 22: 5721-5740.
77. Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM et al. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem 2005; 280: 17005-17012.
78. Barnes BJ, Field AE, Pitha-Rowe PM. Virus-induced heterodimer formation-between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. J Biol Chem 2003; 278: 16630-16641.
79. Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem 2004; 279: 45194-45207.
80. Bolland S, Ravetch JV. Spontaneous autoimmune disease in FcgRIIB-deficient mice results from strain-specific epistasis. Immunity 2000; 13: 277-285.
81. Bolland S, Yim YS, Tus K, Wakeland EK, Ravetch JV. Genetic modifiers of systemic lupus erythematosus in FcgRIIB(-/-) mice. J Exp Med 2002; 195: 1167-1174.
82. Murphy ED, Roths JB. A Y chromosome associated factor in strain BXSB producing accelerated autoimmunity and lymphoproliferation. Arthritis Rheum 1979; 22: 1188-1194.
83. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006; 312: 1669-1672.
84. Subramanian S, Tus K, Li QZ, Wang A, Tian XH, Zhou J et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA 2006; 103: 9970-9975.
85. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005; 434: 243-249.
86. Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW, Takaoka A et al. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci USA 2007; 104: 3402-3407.
87. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38: 550-555.
88. Kozyrev SV, Lewen S, Reddy PM, Pons-Estel B, Witte T, Junker P et al. Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1234-1241.
89. Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, Spielman RS et al. Genetic analysis of genome-wide variation in human gene expression. Nature 2004; 430: 743-747.
90. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, Burdick JT. Mapping determinants of human gene expression by regional and genome-wide association. Nature 2005; 437: 1365-1369.
91. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, Baechler EC et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 2007; 104: 6758-6763.
92. The International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
93. Conne B, Stutz A, Vassalli JD. The 3′ untranslated region of messenger RNA: A molecular. Nat Med 2000; 6: 637-641.
94. Edmonds M. A history of poly A sequences: From formation to factors to function. Prog Nucleic Acid Res Mol Biol 2002; 71: 285-389.
95. Mendez R, Richter JD. Translational control by CPEB: A means to the end. Nat Rev Mol Cell Biol 2001; 2: 521-529.
96. Cunninghame Graham DS, Manku H, Wagner S, Reid J, Timms K, Gutin A et al. Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. Hum Mol Genet 2007; 16: 579-591.
97. Levi BZ, Hashmueli S, Gleit-Kielmanowicz M, Azriel A, Meraro D. ICSBP/ IRF-8 transactivation: A tale of protein-protein interaction. J Interferon Cytokine Res 2002; 22: 153-160.
98. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: All roads lead to type I interferons. Curr Opin Immunol 2006; 18 676-682.
99. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematcsus and other autoimmune diseases. Immunity 2006; 25 383-392.
100. Graham RR, Ortmann WA, Langefeld CD, Jawaheer D, Selby SA, Rodine PR et al. Visualizing human leukocyte antigen class II risk haplotypes in human systemic lupus erythematosus. Am J Hum Genet 2002; 71 543-553.
101. Shin HD, Sung YK, Choi CB, Lee SO, Lee HW, Bae SC. Replication of the genetic effects of IFN regulatory factor 5 (IRF5) on systemic lupus erythematosus in a Korean population. Arthritis Res Ther 2007; 9: R32.
102. Cann HM, de Toma C, Cazes L, Legrand MF, Morel V, Piouffre L et al. A human genome diversity cell line panel. Science 2002; 296 261-262.
103. Fanzo JC, Yang W, Jang SY, Gupta S, Chen Q, Siddiq A et al. Loss of IRF-4-binding protein leads to the spontaneous development of systemic autoimmunity. J Clin Invest 2006; 116: 703-714.
104. Akahoshi M, Nakashima H, Shirakawa T. Roles of genetic variations in signalling/immunoregulatory molecules in susceptibility to systemic lupus erythematosus. Semin Immunol 2006; 18: 224-229.